Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4825) 4825
Book Review (846) 846
Publication (406) 406
Newsletter (44) 44
Book Chapter (43) 43
Book / eBook (18) 18
Conference Proceeding (10) 10
Dissertation (4) 4
Newspaper Article (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4684) 4684
humans (4522) 4522
leukemia, myeloid, acute - enzymology (1339) 1339
oncology (1306) 1306
animals (1278) 1278
female (1166) 1166
hematology (1166) 1166
male (1139) 1139
leukemia (1055) 1055
adult (910) 910
acute myeloid-leukemia (869) 869
cancer (837) 837
middle aged (814) 814
aged (645) 645
mice (623) 623
cell line, tumor (604) 604
apoptosis (596) 596
leukemia - enzymology (564) 564
leukemia, myeloid - enzymology (564) 564
cell biology (522) 522
mutation (492) 492
leukemia, myeloid, acute - pathology (478) 478
abridged index medicus (475) 475
antineoplastic agents - pharmacology (472) 472
biochemistry & molecular biology (471) 471
apoptosis - drug effects (464) 464
adolescent (457) 457
leukemia, myeloid, acute - drug therapy (440) 440
expression (437) 437
child (432) 432
research (432) 432
leukemia, myeloid, acute - genetics (430) 430
acute disease (407) 407
antineoplastic agents - therapeutic use (391) 391
neoplasms - enzymology (376) 376
acute lymphoblastic-leukemia (375) 375
protein kinase inhibitors - pharmacology (352) 352
cell line (350) 350
tumor cells, cultured (346) 346
genetic aspects (338) 338
proteins (336) 336
signal transduction (335) 335
pharmacology & pharmacy (332) 332
phosphorylation (327) 327
gene expression (317) 317
leukemia, lymphoid - enzymology (296) 296
leukemia, myelogenous, chronic, bcr-abl positive - enzymology (294) 294
cells (292) 292
differentiation (289) 289
hemic and lymphatic diseases (285) 285
analysis (280) 280
prognosis (279) 279
acute myeloid leukemia (271) 271
protein kinase inhibitors - therapeutic use (267) 267
chronic myeloid-leukemia (263) 263
enzyme inhibitors - pharmacology (263) 263
enzymes (258) 258
child, preschool (257) 257
precursor cell lymphoblastic leukemia-lymphoma - enzymology (256) 256
chronic myelogenous leukemia (255) 255
activation (251) 251
signal transduction - drug effects (246) 246
health aspects (245) 245
leukocytes - enzymology (243) 243
physiological aspects (240) 240
neoplasms - drug therapy (239) 239
article (234) 234
bone marrow - enzymology (234) 234
cell proliferation - drug effects (234) 234
kinases (226) 226
cell differentiation (223) 223
chemotherapy (219) 219
medicine, research & experimental (213) 213
research article (213) 213
care and treatment (211) 211
hl-60 cells (207) 207
time factors (207) 207
imatinib mesylate (206) 206
tumors (205) 205
medicine (204) 204
leukemia, myeloid - pathology (202) 202
cell differentiation - drug effects (197) 197
acute myelogenous leukemia (196) 196
aml (194) 194
gene (194) 194
multidisciplinary sciences (194) 194
aged, 80 and over (192) 192
drug resistance, neoplasm (189) 189
flow cytometry (182) 182
protein-tyrosine kinases - antagonists & inhibitors (182) 182
histocytochemistry (180) 180
leukemia - pathology (180) 180
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (177) 177
dose-response relationship, drug (175) 175
in-vitro (175) 175
molecular sequence data (175) 175
acute promyelocytic leukemia (172) 172
cell proliferation (171) 171
gene-expression (171) 171
gene expression regulation, neoplastic (170) 170
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4596) 4596
German (84) 84
Russian (57) 57
French (41) 41
Japanese (32) 32
Chinese (26) 26
Polish (20) 20
Italian (17) 17
Czech (7) 7
Spanish (4) 4
Bulgarian (2) 2
Croatian (2) 2
Dutch (2) 2
Serbian (2) 2
Ukrainian (2) 2
Danish (1) 1
Hungarian (1) 1
Norwegian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N-6-Methyladenosine RNA Demethylase
by Li, ZJ and Weng, HY and Su, R and Weng, XC and Zuo, ZX and Li, CY and Huang, HL and Nachtergaele, S and Dong, L and Hu, C and Qin, X and Tang, LC and Wang, YG and Hong, GM and Huang, H and Wang, X and Chen, P and Gurbuxani, S and Arnovitz, S and Li, YY and Li, SL and Strong, J and Neilly, MB and Larson, RA and Jiang, X and Zhang, PM and Jin, J and He, C and Chen, JJ
CANCER CELL, ISSN 1535-6108, 01/2017, Volume 31, Issue 1, pp. 127 - 141
N-6-Methyladenosine (m(6)A) represents the most prevalent internal modification in mammalian mRNAs. Despite its functional importance in various fundamental... 
AML CELLS | OBESITY-ASSOCIATED FTO | MESSENGER-RNA | ONCOLOGY | GENE-EXPRESSION REGULATION | TRANS-RETINOIC ACID | NUCLEAR-RNA | ADULT OBESITY | ACUTE PROMYELOCYTIC LEUKEMIA | MLL-REARRANGED LEUKEMIA | ARSENIC TRIOXIDE | CELL BIOLOGY | Cell Proliferation | Leukemia, Myeloid, Acute - pathology | Alpha-Ketoglutarate-Dependent Dioxygenase FTO - physiology | Humans | Transcriptome | Leukemia, Myeloid, Acute - etiology | Retinoic Acid Receptor alpha - physiology | Leukemia, Myeloid, Acute - enzymology | Adenosine - analogs & derivatives | Adenosine - metabolism | Leukemia, Myeloid, Acute - drug therapy | Suppressor of Cytokine Signaling Proteins - physiology | Methylation | Apoptosis | Tretinoin - pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Sorafenib treatment of FLT3-ITD + acute myeloid leukemia: Favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
by Man, Cheuk Him and Fung, Tsz Kan and Ho, Christa and Han, Heron H. C and Chow, Howard C. H and Ma, Alvin C. H and Choi, William W. L and Lok, Si and Cheung, Alice M. S and Eaves, Connie and Kwong, Yok Lam and Leung, Anskar Y. H
Blood, ISSN 0006-4971, 06/2012, Volume 119, Issue 22, pp. 5133 - 5143
Internal tandem duplication (ITD) of the fms-related tyrosine kinase-3 (FLT3) gene occurs in 30% of acute myeloid leukemias (AMLs) and confers a poor... 
FLT3 TYROSINE KINASE | INTERNAL TANDEM DUPLICATION | ADULT PATIENTS | ACTIVATING MUTATION | INHIBITOR PKC412 | ALDEHYDE DEHYDROGENASE-ACTIVITY | ACUTE MYELOGENOUS LEUKEMIA | TISSUE INHIBITOR | RISK MYELODYSPLASTIC SYNDROME | PROGNOSTIC-SIGNIFICANCE | HEMATOLOGY | Niacinamide - analogs & derivatives | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Neoplasm Transplantation | Humans | Middle Aged | Aldehyde Dehydrogenase - biosynthesis | Matrix Metalloproteinase 15 - genetics | Male | Transplantation, Heterologous | Bone Marrow - enzymology | Gene Expression Profiling | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Benzenesulfonates - adverse effects | Janus Kinase 3 - biosynthesis | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myeloid, Acute - enzymology | Pyridines - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Protein Structure, Tertiary | Pyridines - administration & dosage | Leukemia, Myeloid, Acute - pathology | Aldehyde Dehydrogenase - genetics | Gene Expression Regulation, Leukemic | Mice, SCID | fms-Like Tyrosine Kinase 3 - metabolism | Matrix Metalloproteinase 15 - biosynthesis | Drug Resistance, Neoplasm - genetics | Animals | Bone Marrow - pathology | Janus Kinase 3 - genetics | Mice, Inbred NOD | Mice | Mutation | Drug Resistance, Neoplasm - drug effects | Leukemia, Myeloid, Acute - genetics | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
by Okoye-Okafor, Ujunwa C and Bartholdy, Boris and Cartier, Jessy and Gao, Enoch N and Pietrak, Beth and Rendina, Alan R and Rominger, Cynthia and Quinn, Chad and Smallwood, Angela and Wiggall, Kenneth J and Reif, Alexander J and Schmidt, Stanley J and Qi, Hongwei and Zhao, Huizhen and Joberty, Gerard and Faelth-Savitski, Maria and Bantscheff, Marcus and Drewes, Gerard and Duraiswami, Chaya and Brady, Pat and Groy, Arthur and Narayanagari, Swathi-Rao and Antony-Debre, Iléana and Mitchell, Kelly and Wang, Heng Rui and Kao, Yun-Ruei and Christopeit, Maximilian and Carvajal, Luis and Barreyro, Laura and Paietta, Elisabeth and Makishima, Hideki and Will, Britta and Concha, Nestor and Adams, Nicholas D and Schwartz, Benjamin and McCabe, Michael T and Maciejewski, Jaroslav and Verma, Amit and Steidl, Ulrich and Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Nature Chemical Biology, ISSN 1552-4450, 11/2015, Volume 11, Issue 11, pp. 878 - 886
Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are driver mutations in acute myeloid leukemia (AML) and other cancers. We report the development of... 
ISOCITRATE DEHYDROGENASE 1 | SELECTIVE-INHIBITION | PROGENITOR CELLS | DNA METHYLATION | SMALL-MOLECULE | BIOCHEMISTRY & MOLECULAR BIOLOGY | CLINICAL-IMPLICATIONS | KINASE INHIBITORS | CELL-DIFFERENTIATION | MYELODYSPLASTIC SYNDROMES | ACUTE PROMYELOCYTIC LEUKEMIA | Neoplastic Stem Cells - drug effects | Allosteric Regulation | Humans | Crystallography, X-Ray | Male | Isocitrate Dehydrogenase - antagonists & inhibitors | Dose-Response Relationship, Drug | Leukemia, Myeloid, Acute - enzymology | Pyrazoles - chemistry | Enzyme Inhibitors - pharmacokinetics | Granulocytes - drug effects | Cytosine - metabolism | Dihydropyridines - pharmacokinetics | Enzyme Inhibitors - chemistry | Leukemia, Myeloid, Acute - drug therapy | Neoplastic Stem Cells - pathology | Granulocytes - pathology | Pyrazoles - pharmacokinetics | Pyrazoles - pharmacology | Dihydropyridines - chemistry | Leukemia, Myeloid, Acute - pathology | Enzyme Inhibitors - pharmacology | Models, Molecular | Isocitrate Dehydrogenase - genetics | Cytosine - chemistry | Granulocytes - enzymology | Xenograft Model Antitumor Assays | Animals | Cell Differentiation - drug effects | Isocitrate Dehydrogenase - chemistry | Allosteric Site | Cell Line, Tumor | CpG Islands | Dihydropyridines - pharmacology | Protein Binding | Isocitrate Dehydrogenase - metabolism | Mice | Kinetics | Mutation | Primary Cell Culture | DNA Methylation - drug effects | Neoplastic Stem Cells - enzymology | Leukemia, Myeloid, Acute - genetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
by Zimmerman, Eric I and Zimmerman, Eric I and Turner, David C and Turner, David C and Buaboonnam, Jassada and Buaboonnam, Jassada and Hu, Shuiying and Hu, Shuiying and Orwick, Shelley and Orwick, Shelley and Roberts, Michael S and Roberts, Michael S and Janke, Laura J and Janke, Laura J and Ramachandran, Abhijit and Ramachandran, Abhijit and Stewart, Clinton F and Stewart, Clinton F and Inaba, Hiroto and Inaba, Hiroto and Baker, Sharyn D and Baker, Sharyn D
Blood, ISSN 0006-4971, 2013, Volume 122, Issue 22, pp. 3607 - 3615
FLT3 kinase internal tandem duplication (ITD) mutations are common in acute myeloid leukemia (AML) and are associated with poor clinical outcomes. Although... 
GASTROINTESTINAL STROMAL TUMOR | PONATINIB | FLT3 | THERAPEUTIC TARGET | IMATINIB | MECHANISMS | INHIBITORS | MUTATIONS | SORAFENIB | HEMATOLOGY | CYTOGENETICS | Niacinamide - analogs & derivatives | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Humans | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Tandem Repeat Sequences | Antineoplastic Agents - administration & dosage | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myeloid, Acute - enzymology | Benzimidazoles - administration & dosage | Leukemia, Myeloid, Acute - drug therapy | Female | Piperidines - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | Benzimidazoles - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Cell Survival - drug effects | Piperidines - administration & dosage | Benzimidazoles - pharmacokinetics | Mice, SCID | Niacinamide - administration & dosage | Drug Synergism | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Phenylurea Compounds - administration & dosage | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Mice, Inbred NOD | Mice | Mutation | Leukemia, Myeloid, Acute - genetics | Index Medicus | Abridged Index Medicus | Myeloid Neoplasia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia
by Felicitas Thol and Frederik Damm and Andrea Lüdeking and Claudia Winschel and Katharina Wagner and Michael Morgan and Haiyang Yun and Gudrun Göhring and Brigitte Schlegelberger and Dieter Hoelzer and Michael Lübbert and Lothar Kanz and Walter Fiedler and Hartmut Kirchner and Gerhard Heil and Jürgen Krauter and Arnold Ganser and Michael Heuser
Journal of Clinical Oncology, ISSN 0732-183X, 07/2011, Volume 29, Issue 21, pp. 2889 - 2896
Purpose To study the incidence and prognostic impact of mutations in DNA methyltransferase 3A (DNMT3A) in patients with acute myeloid leukemia. Patients and... 
GENE-MUTATIONS | AML | TRIAL | DIAGNOSIS | NORMAL KARYOTYPE | ONCOLOGY | RECOMMENDATIONS | NORMAL CYTOGENETICS | ADULTS | RESISTANCE | EXPRESSION PROFILES | Age Factors | Humans | Middle Aged | DNA (Cytosine-5-)-Methyltransferases - metabolism | Young Adult | DNA Methylation | Leukemia, Myeloid, Acute - enzymology | Time Factors | DNA Mutational Analysis | Biomarkers, Tumor - metabolism | Adult | Leukemia, Myeloid, Acute - therapy | Genetic Predisposition to Disease | Risk Assessment | Risk Factors | Survival Rate | Treatment Outcome | Gene Expression Regulation, Leukemic | Leukemia, Myeloid, Acute - mortality | DNA (Cytosine-5-)-Methyltransferases - genetics | Disease-Free Survival | Adolescent | Survival Analysis | Biomarkers, Tumor - genetics | Mutation | Germany | Leukemia, Myeloid, Acute - genetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
by Cole, Alicia and Wang, Xiaoming and Wang, Jean C.Y and Wang, Zezhou and Coyaud, Etienne and Voisin, Veronique and Gronda, Marcela and Jitkova, Yulia and Mattson, Rachel and Hurren, Rose and Babovic, Sonja and Maclean, Neil and Restall, Ian and Jeyaraju, Danny V and Sukhai, Mahadeo A and Prabha, Swayam and Bashir, Shaheena and Ramakrishnan, Ashwin and Leung, Elisa and Qia, Yi Hua and Zhang, Nianxian and Combes, Kevin R and Ketela, Troy and Lin, Fengshu and Houry, Walid A and Aman, Ahmed and Al-awar, Rima and Zheng, Wei and Wienholds, Erno and Xu, Chang Jiang and Dick, John and Moffat, Jason and Minden, Mark D and Eaves, Connie J and Bader, Gary D and Hao, Zhenyue and Kornblau, Steven M and Raught, Brian and Schimmer, Aaron D
Cancer Cell, ISSN 1535-6108, 06/2015, Volume 27, Issue 6, pp. 864 - 876
From an shRNA screen, we identified ClpP as a member of the mitochondrial proteome whose knockdown reduced the viability of K562 leukemic cells. Expression of... 
ADVERSE PROGNOSTIC-FACTOR | CARFILZOMIB | ONCOLOGY | TARGETS | BORTEZOMIB | EXPRESSION | HUMAN HOMOLOG | SOFTWARE | CELL BIOLOGY | RNA, Small Interfering - genetics | Humans | Enzyme Inhibitors - pharmacology | Male | Endopeptidase Clp - metabolism | Mice, SCID | Endopeptidase Clp - antagonists & inhibitors | Mice, Knockout | Leukemia, Myeloid, Acute - enzymology | Animals | Heterografts | Leukemia, Myeloid, Acute - drug therapy | Mice | Physiological aspects | Drug discovery | Molecular genetics | Proteases | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Mutant DNMT3A: A marker of poor prognosis in acute myeloid leukemia
by Ribeiro, Ana and Pratcorona, Marta and Erpelinck-Verschueren, C. A J and Rockova, Veronika and Sanders, Mathijs and Abbas, Saman and Figueroa, Maria Eugenia and Zeilemaker, Annelieke and Melnick, Ari and Löwenberg, Bob and Valk, Peter and Delwel, Ruud
Blood, ISSN 0006-4971, 06/2012, Volume 119, Issue 24, pp. 5824 - 5831
The prevalence, the prognostic effect, and interaction with other molecular markers of DNMT3A mutations was studied in 415 patients with acute myeloid leukemia... 
AML | MAINTENANCE | DNA METHYLATION PATTERNS | NUCLEOPHOSMIN | SIGNATURES | METHYLTRANSFERASES | GENE-EXPRESSION | MAMMALIAN DEVELOPMENT | MUTATIONS | HEMATOLOGY | BINDING | Multivariate Analysis | Recurrence | Prognosis | Humans | Middle Aged | Male | Gene Expression Profiling | Neoplasm Proteins - metabolism | Biomarkers, Tumor | Young Adult | Leukemia, Myeloid, Acute - enzymology | Adult | Female | Neoplasm Proteins - genetics | Leukemia, Myeloid, Acute - therapy | Mutant Proteins - metabolism | Treatment Outcome | DNA Methylation - genetics | Gene Expression Regulation, Leukemic | Mutation - genetics | DNA (Cytosine-5-)-Methyltransferases - genetics | Leukemia, Myeloid, Acute - diagnosis | Adolescent | Survival Analysis | Cluster Analysis | Leukemia, Myeloid, Acute - genetics | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia
by Guido Marcucci and Klaus H. Metzeler and Sebastian Schwind and Heiko Becker and Kati Maharry and Krzysztof Mrózek and Michael D. Radmacher and Jessica Kohlschmidt and Deedra Nicolet and Susan P. Whitman and Yue-Zhong Wu and Bayard L. Powell and Thomas H. Carter and Jonathan E. Kolitz and Meir Wetzler and Andrew J. Carroll and Maria R. Baer and Joseph O. Moore and Michael A. Caligiuri and Richard A. Larson and Clara D. Bloomfield
Journal of Clinical Oncology, ISSN 0732-183X, 03/2012, Volume 30, Issue 7, pp. 742 - 750
Purpose To determine the frequency of DNMT3A mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene-and... 
GENE-MUTATIONS | INTERNAL TANDEM DUPLICATION | OLDER PATIENTS | ONCOLOGY | FAVORABLE PROGNOSIS | POOR-PROGNOSIS | MICRORNA-EXPRESSION SIGNATURES | MYELOGENOUS LEUKEMIA | YOUNGER ADULTS | GROUP-B | RESISTANCE MODULATOR PSC-833 | Prognosis | Age Factors | Humans | Middle Aged | Male | Gene Expression Profiling | Young Adult | DNA (Cytosine-5-)-Methyltransferases - genetics | Leukemia, Myeloid, Acute - enzymology | Adolescent | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Mutation | Leukemia, Myeloid, Acute - genetics | Index Medicus | Hema8 | To19 | Hema4 | ORIGINAL REPORTs | Hema9
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
by Gross, Stefan and Cairns, Rob A and Minden, Mark D and Driggers, Edward M and Bittinger, Mark A and Jang, Hyun Gyung and Sasaki, Masato and Jin, Shengfang and Schenkein, David P and Su, Shinsan M and Dang, Lenny and Fantin, Valeria R and Mak, Tak W
Journal of Experimental Medicine, ISSN 0022-1007, 02/2010, Volume 207, Issue 2, pp. 339 - 344
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), are present in most gliomas and secondary glioblastomas, but are rare in other neoplasms. IDH1/2... 
GLIOMAS | MEDICINE, RESEARCH & EXPERIMENTAL | IDH2 MUTATIONS | OXIDATIVE STRESS | CODON 132 MUTATION | ESCHERICHIA-COLI | ACIDURIA | DEFECT | IMMUNOLOGY | TUMORS | BRAIN | Recombinant Proteins - metabolism | Leukemia, Myeloid, Acute - enzymology | Humans | Isocitrate Dehydrogenase - genetics | Isocitrate Dehydrogenase - metabolism | Leukemia, Myeloid, Acute - blood | Catalysis | Mutation | NADP - metabolism | Glutarates - blood | Ketoglutaric Acids - metabolism | Leukemia, Myeloid, Acute - genetics | Index Medicus | Brief Definitive Report
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia
by Keeton, Erika K and McEachern, Kristen and Dillman, Keith S and Palakurthi, Sangeetha and Cao, Yichen and Grondine, Michael R and Kaur, Surinder and Wang, Suping and Chen, Yuching and Wu, Allan and Shen, Minhui and Gibbons, Francis D and Lamb, Michelle L and Zheng, Xiaolan and Stone, Richard M and DeAngelo, Daniel J and Platanias, Leonidas C and Dakin, Les A and Chen, Huawei and Lyne, Paul D and Huszar, Dennis
Blood, ISSN 0006-4971, 02/2014, Volume 123, Issue 6, pp. 905 - 913
Upregulation of Pim kinases is observed in several types of leukemias and lymphomas. Pim-1, -2, and -3 promote cell proliferation and survival downstream of... 
SURVIVAL | PROTEIN | PHOSPHORYLATION | BAD | FLT3 | THERAPEUTIC TARGET | SIZE | CELL-GROWTH | TRANSLATION | HEMATOLOGY | EXPRESSION | Protein Kinase Inhibitors - pharmacokinetics | Biphenyl Compounds - pharmacokinetics | Thiazolidines - pharmacokinetics | Enzyme-Linked Immunosorbent Assay | Apoptosis - drug effects | Leukemia, Myeloid, Acute - pathology | Humans | Proto-Oncogene Proteins c-pim-1 - metabolism | Mice, SCID | Blotting, Western | Tissue Distribution | Leukemia, Myeloid, Acute - enzymology | Animals | Biphenyl Compounds - pharmacology | Cell Cycle | Proto-Oncogene Proteins c-pim-1 - antagonists & inhibitors | Leukemia, Myeloid, Acute - drug therapy | Female | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Tumor Cells, Cultured | Thiazolidines - pharmacology | Index Medicus | Abridged Index Medicus | Myeloid Neoplasia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
by Walter, M.J and Ding, L and Shen, D and Shao, J and Grillot, M and McLellan, M and Fulton, R and Schmidt, H and Kalicki-Veizer, J and O'Laughlin, M and Kandoth, C and Baty, J and Westervelt, P and Dipersio, J.F and Mardis, E.R and Wilson, R.K and Ley, T.J and Graubert, T.A
Leukemia, ISSN 0887-6924, 07/2011, Volume 25, Issue 7, pp. 1153 - 1158
Alterations in DNA methylation have been implicated in the pathogenesis of myelodysplastic syndromes (MDS), although the underlying mechanism remains largely... 
myelodysplastic syndrome | mutation | DNMT3A | MUTANT TET2 | METHYLATION | NEOPLASMS | METHYLTRANSFERASE GENE EZH2 | ALPHA | HYPOMETHYLATION | ONCOLOGY | COMMON | LEUKEMIA | MYELOID CANCERS | HEMATOLOGY | NOVO DNA METHYLTRANSFERASE | Prognosis | Humans | Middle Aged | Male | Granulocyte Precursor Cells - enzymology | Myelodysplastic Syndromes - enzymology | Young Adult | Leukemia, Myeloid, Acute - enzymology | Aged, 80 and over | Adult | Female | Codon - genetics | Kaplan-Meier Estimate | Exons - genetics | DNA Methylation - genetics | Sequence Analysis, DNA | Disease Progression | Leukemia, Myeloid, Acute - mortality | DNA (Cytosine-5-)-Methyltransferases - genetics | Myelodysplastic Syndromes - mortality | CpG Islands - genetics | Aged | Myelodysplastic Syndromes - genetics | DNA, Neoplasm - genetics | Mutation | Leukemia, Myeloid, Acute - genetics | Gene mutations | DNA | Physiological aspects | Development and progression | Genetic aspects | Research | Methylation | Health aspects | Myelodysplastic syndromes | Risk factors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
by Licht, Jonathan D and Gelb, Bruce D and Jung, Andreas and Fragale, Alessandra and Song, Xiaoling and Buechner, Jochen and Niemeyer, Charlotte M and Tartaglia, Marco and Hählen, Karel and Hasle, Henrik
Nature Genetics, ISSN 1061-4036, 06/2003, Volume 34, Issue 2, pp. 148 - 150
We report here that individuals with Noonan syndrome and juvenile myelomonocytic leukemia (JMML) have germline mutations in PTPN11 and that somatic mutations... 
NOONAN-SYNDROME | TYROSINE-PHOSPHATASE SHP-2 | GENETICS & HEREDITY | Leukemia, Myelomonocytic, Acute - genetics | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | Noonan Syndrome - enzymology | Leukemia, Myelomonocytic, Acute - complications | Humans | Intracellular Signaling Peptides and Proteins | Protein Tyrosine Phosphatases - metabolism | Noonan Syndrome - genetics | Myelodysplastic Syndromes - enzymology | Noonan Syndrome - complications | Leukemia, Myeloid, Acute - enzymology | Protein Tyrosine Phosphatases - genetics | Animals | Transfection | Leukemia, Myelomonocytic, Acute - enzymology | Myelodysplastic Syndromes - genetics | Mutation | COS Cells | Child | Leukemia, Myeloid, Acute - genetics | Complications and side effects | Genetic aspects | Diagnosis | Gene mutations | Risk factors | Cancer in children | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
by Thomas Fischer and Richard M. Stone and Daniel J. DeAngelo and Ilene Galinsky and Elihu Estey and Carlo Lanza and Edward Fox and Gerhard Ehninger and Eric J. Feldman and Gary J. Schiller and Virginia M. Klimek and Stephen D. Nimer and D. Gary Gilliland and Catherine Dutreix and Alice Huntsman-Labed and Jodi Virkus and Francis J. Giles
Journal of Clinical Oncology, ISSN 0732-183X, 10/2010, Volume 28, Issue 28, pp. 4339 - 4345
Purpose Mutations leading to constitutive activation of the FMS-like tyrosine kinase 3 receptor (FLT3) occur in blasts of 30% of patients with acute myeloid... 
AML | MODEL | RESPONSE CRITERIA | ONCOLOGY | CHEMOTHERAPY | INTERNATIONAL WORKING GROUP | Administration, Oral | Humans | Staurosporine - adverse effects | Male | Staurosporine - analogs & derivatives | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Myelodysplastic Syndromes - enzymology | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myeloid, Acute - enzymology | Receptor Protein-Tyrosine Kinases - genetics | Antineoplastic Agents - adverse effects | Staurosporine - therapeutic use | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Myelodysplastic Syndromes - genetics | Mutation | Myelodysplastic Syndromes - drug therapy | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Index Medicus | Hema7 | ORIGINAL REPORTS | Bios3
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights